Walker Neal 4

What Happened

• Walker Neal, a director of Aldeyra Therapeutics, received two awards on 2026-06-09 totaling 73,318 derivative shares (70,000 and 3,318). Each award shows an acquisition price of $0.00, so no cash was paid. These are grant/award transactions (code A) and are not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-09; Form filed: 2026-06-11 (timely).
• Awards: 70,000 shares (footnote F1) and 3,318 shares (footnote F2); price per share $0.00; total awarded = 73,318 shares.
• Vesting/Exercisability: F1 — 100% exercisable on the one‑year anniversary of the grant if Neal continues as a Board member; F2 — 100% exercisable on the one‑year anniversary if he continues as a member of the Compensation Committee.
• Shares owned after transaction: Not specified in the provided filing.
• Transaction type: Derivative award/compensation (code A), not a market buy or sale.

Context

• These awards appear to be compensation/retention grants to a director and should not be interpreted as an open‑market bullish purchase or a sale. The derivatives become exercisable only after one year of continuous service per the footnotes, so they are not immediately tradable.